Alloxan-induced diabetes causes morphological and ultrastructural changes in rat liver that resemble the natural history of chronic fatty liver disease in humans

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Lucchesi, Amanda Natália ^a   Cassettari, Lucas Langoni ^a   Spadella, César Tadeu ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; INSULIN; ALLOXAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELL NUCLEUS; CELL ORGANELLE; CONTROLLED STUDY; FATTY LIVER; HEPATOMEGALY; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIVER; LIVER CELL; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER MITOCHONDRION; LIVER SINUSOID; LIVER STRUCTURE; LIVER WEIGHT; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; ROUGH ENDOPLASMIC RETICULUM; ULTRASTRUCTURE; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; LIVER CIRRHOSIS; METABOLISM; ORGAN SIZE; PATHOPHYSIOLOGY; TIME; TRANSMISSION ELECTRON MICROSCOPY; WISTAR RAT;

ALANINE TRANSAMINASE; ALLOXAN; ANIMALS; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; CELL NUCLEUS; CHRONIC DISEASE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATOCYTES; INSULIN; LIVER; LIVER CIRRHOSIS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; ORGAN SIZE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84924227542     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/494578     Document Type: Article

References (45)

1. G. C. Farrell and C. Z. Larter, "Nonalcoholic fatty liver disease: from steatosis to cirrhosis," Hepatology, vol. 43, no. 2, pp. S99-S112, 2006.
2. B.W. Smith and L. A. Adams, "Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment," Nature Reviews Endocrinology, vol. 7, no. 8, pp. 456-465, 2011.
3. H. Ahmadieh and S. T. Azar, "Liver disease and diabetes: association, pathophysiology, and management," Diabetes Research and Clinical Practice, vol. 104, no. 1, pp. 53-62, 2014.
4. V. G. Kozyritskij and A. G. Minchenko, "Ultrastructural alterations in rat hepatocytes under diabetes and insulin administration," Tsitologiya i Genetika, vol. 12, no. 5, pp. 397-401, 1978.
5. K. Welt, J. Weiss, R. Martin et al., "Ultrastructural, immunohistochemical and biochemical investigations of the rat liver exposed to experimental diabetes and acute hypoxia with and without application of Ginkgo extract," Experimental and Toxicologic Pathology, vol. 55, no. 5, pp. 331-345, 2004.
6. R. N. Remedio, A. Castellar, R. A. Barbosa, R. J. Gomes, and F. H. Caetano, "Morphology and protein content of hepatocytes in type I diabetic rats submitted to physical exercises," Micron, vol. 42, no. 5, pp. 484-491, 2011.
7. R. P. Laguens, S. Candela, R. E. Hernández, and J. J.Gagliardino, "Streptozotocin-induced liver damage in mice," Hormone and Metabolic Research, vol. 12, no. 5, pp. 197-201, 1980.
8. E.Kume,Y.Ohmachi, S. Itagaki,K. Tamura, andK.Doi, "Hepatic changes ofmice in the subacute phase of streptozotocin (SZ)-induced diabetes," Experimental and Toxicologic Pathology, vol. 46, no. 4-5, pp. 368-374, 1994.
9. A. B. Mahmoud and M. B. Al-Salahy, "Physiological and histological studies on the effect of lupine seeds on the fish, Clarias lazera treated with glucose and alloxan," Fish Physiology and Biochemistry, vol. 30, no. 3-4, pp. 213-229, 2004.
10. B. Can, N. N. Ulusu, K. Kilinç, N. L. Acan, Y. Saran, and B. Turan, "Selenium treatment protects diabetes-induced biochemical and ultrastructural alterations in liver tissue," Biological Trace Element Research, vol. 105, no. 1-3, pp. 135-150, 2005.
11. W. Dąbrós, A. Goc, B. Turyna, and A. M. Kordowiak, "Sodium metavanadate affected control and streptozotocin-diabetic rat liver golgi complexes," Polish Journal of Pathology, vol. 57, no. 2, pp. 91-97, 2006.
12. A. Guven, O. Yavuz, M. Cam et al., "Effects of melatonin on streptozotocin-induced diabetic liver injury in rats," Acta Histochemica, vol. 108, no. 2, pp. 85-93, 2006.
13. S. O. Adewole and J. A. O. Ojewole, "Artocarpus communis forst. Root-bark aqueous extract-and streptozotocin-induced ultrastructural andmetabolic changes hepatic tissues ofWistar rats," African Journal of Traditional, Complementary and Alternative Medicines, vol. 4, no. 4, pp. 397-410, 2007.
14. P. Evelson, C. Susemihl, I. Villarreal et al., "Hepatic morphological changes and oxidative stress in chronic streptozotocindiabetic rats," Annals of Hepatology, vol. 4, no. 2, pp. 115-120, 2005.
15. N. C. Leite, C. A. Villela-Nogueira, V. L. N. Pannain et al., "Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors," Liver International, vol. 31, no. 5, pp. 700-706, 2011.
16. S. E. Regnell and A. Lernmark, "Hepatic steatosis in type 1 diabetes," Review of Diabetic Studies, vol. 84, no. 4, pp. 454-467, 2011.
17. J. P. Verderese and Z. Younossi, "Interaction of Type 2 diabetes and nonalcoholic fatty liver disease," Expert Review of Gastroenterology and Hepatology, vol. 7, no. 5, pp. 405-407, 2013.
18. P. Portincasa, I. Grattagliano,V.O. Palmieri, andG. Palasciano, "Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management," Clinical Biochemistry, vol. 38, no. 3, pp. 203-217, 2005.
19. J. Shaw Dunn, H. L. Sheehan, and N. G. B.Mcletchie, "Necrosis of islets of Langerhans produced experimentally," The Lancet, vol. 241, no. 6242, pp. 484-487, 1943.
20. A. Junod, A. E. Lambert, L. Orci, R. Pictet, A. E. Gonet, and A. E. Renold, "Studies of the diabetogenic action of streptozotocin," Proceedings of the Society for Experimental Biology and Medicine, vol. 126, no. 1, pp. 201-205, 1967.
21. F. D. Lukens, "Alloxan diabetes.," Physiological reviews, vol. 28, no. 3, pp. 304-330, 1948.
22. K. A. Goel, "Submassive necrosis of liver of Channa gachua, a fresh water fish during experimental alloxan diabetes," Anatomischer Anzeiger, vol. 141, no. 2, pp. 130-135, 1977.
23. C. Voss, K. Brachmann, and K. Hartmann, "Effect of streptozotocin on transaminase, creatinine and urea in serum of rats," Experimental and Clinical Endocrinology, vol. 92, no. 1, pp. 37-42, 1988.
24. W. E. Abdel-Aal, I. M. Abdel-Nabi, R. A. Hanna, and K. A. Mahdy, "Biochemical and histological changes in normal and alloxan-diabetic rats after lupine seeds administration," Egyptian German Society of Zoology, vol. 10, pp. 252-267, 1993.
25. K. Doi, J. Yamanouchi, E. Kume, and A. Yasoshima, "Morphologic changes in hepatocyte nuclei of streptozotocin (SZ)-induced diabetic mice," Experimental and Toxicologic Pathology, vol. 49, no. 3-4, pp. 295-299, 1997.
26. Z. A. Khan, H. Farhangkhoe, and S. Chakrabarti, "Towards molecular targets for chronic diabetic complication," Current Vascular Pharmacology, vol. 4, pp. 45-57, 2006.
27. H. Kaneto, Y. Nakatani, D. Kawamori et al., "Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic -cell dysfunction and insulin resistance," International Journal of Biochemistry and Cell Biology, vol. 38, no. 5-6, pp. 782-793, 2006.
28. T. Roskams, S. Q. Yang, A. Koteish et al., "Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease," The American Journal of Pathology, vol. 163, no. 4, pp. 1301-1311, 2003.
29. N. Méndez-Sánchez, N. C. Chávez-Tapia, and M. Uribe, "An update on non-alcoholic fatty liver disease," Revista de Investigacion Clinica, vol. 56, no. 1, pp. 72-82, 2004.
30. M. Haque and A. J. Sanyal, "The metabolic abnormalities associated with non-alcoholic fatty liver disease," Bailliere's Best Practice and Research in Clinical Gastroenterology, vol. 16, no. 5, pp. 709-731, 2002.
31. S.Q. Yang, A. K.Mandal, J.Huang, and A.M. Diehl, "Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology," Hepatology, vol. 34, no. 4, pp. 694-706, 2001.
32. A. J.Wigg, I.C. Roberts-Thomson, R. H.Grose, A. G.Cummins, R. B. Dymock, and P. J. McCarthy, "The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor in the pathogenesis of nonalcoholic steatohepatitis," Gut, vol. 48, no. 2, pp. 206-211, 2001.
33. A.N. Lucchesi, N. T. de Freitas, L. L. Cassettari, S.F.G. Marques, and C. T. Spadella, "Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease," Acta Cirurgica Brasileira, vol. 28, no. 7, pp. 502-508, 2013.
34. B. Vergès, "Lipid disorders in type 1 diabetes," Diabetes and Metabolism, vol. 35, no. 5, pp. 353-360, 2009.
35. J. Lenaerts, L. Verresen, W. Van Steenbergen, and J. Fevery, "Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature," Journal of Clinical Gastroenterology, vol. 12, no. 1, pp. 93-97, 1990.
36. J. D. Horton, J. L. Goldstein, and M. S. Brown, "SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver," The Journal of Clinical Investigation, vol. 109, no. 9, pp. 1125-1131, 2002.
37. P. Ferré and F. Foufelle, "SREBP-1c transcription factor and lipid homeostasis: clinical perspective," Hormone Research, vol. 68, no. 2, pp. 72-82, 2007.
38. J. D. Browning and J. D. Horton, "Molecular mediators of hepatic steatosis and liver injury," Journal of Clinical Investigation, vol. 114, no. 2, pp. 147-152, 2004.
39. M. O. Weickert and A. F. H. Pfeiffer, "Signalling mechanisms linking hepatic glucose and lipidmetabolism," Diabetologia, vol. 49, no. 8, pp. 1732-1741, 2006.
40. H. Yamashita, M. Takenoshita, M. Sakurai et al., "A glucoseresponsive transcription factor that regulates carbohydrate metabolism in the liver," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9116-9121, 2001.
41. H. Elasha, S. Alzahrani, M. Almalki, A. Alomair, and W. Alshakweer, "Acute hepatic steatosis: an unusual manifestation of poorly controlled type 1 diabetes," Practical Diabetes International, vol. 27, no. 7, pp. 282-283, 2010.
42. B. Thorens, H. K. Sarkar, H.R. Kaback, and H. F. Lodish, "Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and betapancreatic islet cells," Cell, vol. 55, no. 2, pp. 281-290, 1988.
43. C. Postic, R. Burcelin, F. Rencurel et al., "Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: Studies in vivo and in vitro," Biochemical Journal, vol. 293, no. 1, pp. 119-124, 1993.
44. S. Softic, M. Kirby, N. Shroyer, and R. Kohli, "Hepatic steatosis in type 2 and type 1 diabetes mellitus is mediated by insulin signaling via fatty acid transport proteins," Journal of Pediatric Gastroenterology and Nutrition, vol. 51, supplement 2, pp. E33-E34, 2010.
45. J. K. Dowman, J. W. Tomlinson, and P. N. Newsome, "Pathogenesis of non-alcoholic fatty liver disease," Quarterly Journal of Medicine, vol. 103, no. 2, pp. 71-83, 2009.